AFP
ABBV icon

Ausdal Financial Partners’s AbbVie ABBV Stock Holding History

Ausdal Financial Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.41M Buy
38,690
+777
+2% +$172K 0.37% 58
2025
Q4 		$8.66M Sell
37,913
-189
-0.5% -$43.1K 0.4% 52
2025
Q3 		$8.82M Buy
38,102
+3,506
+10% +$714K 0.43% 41
2025
Q2 		$6.42M Sell
34,596
-1,963
-5% -$365K 0.43% 52
2025
Q1 		$7.66M Buy
36,559
+3,258
+10% +$633K 0.58% 32
2024
Q4 		$5.92M Buy
33,301
+1,670
+5% +$307K 0.51% 43
2024
Q3 		$6.25M Sell
31,631
-456
-1% -$85.1K 0.65% 29
2024
Q2 		$5.5M Buy
32,087
+273
+0.9% +$45.2K 0.59% 32
2024
Q1 		$5.79M Sell
31,814
-620
-2% -$107K 0.67% 27
2023
Q4 		$5.03M Sell
32,434
-974
-3% -$142K 0.62% 30
2023
Q3 		$4.98M Sell
33,408
-177
-0.5% -$26K 0.69% 29
2023
Q2 		$4.52M Sell
33,585
-104
-0.3% -$15.3K 0.61% 30
2023
Q1 		$5.37M Sell
33,689
-1,569
-4% -$240K 0.74% 24
2022
Q4 		$5.7M Buy
35,258
+545
+2% +$83.6K 0.83% 18
2022
Q3 		$4.66M Buy
34,713
+461
+1% +$66.2K 0.74% 24
2022
Q2 		$5.25M Sell
34,252
-904
-3% -$138K 0.79% 25
2022
Q1 		$5.7M Sell
35,156
-4,750
-12% -$690K 0.77% 20
2021
Q4 		$5.4M Sell
39,906
-22,911
-36% -$2.71M 0.72% 23
2021
Q3 		$6.78M Buy
62,817
+12,846
+26% +$1.47M 1.01% 17
2021
Q2 		$5.63M Buy
49,971
+3,727
+8% +$420K 0.85% 22
2021
Q1 		$5M Buy
46,244
+15,080
+48% +$1.61M 0.84% 21
2020
Q4 		$3.34M Buy
31,164
+971
+3% +$93.3K 0.65% 34
2020
Q3 		$2.65M Buy
30,193
+367
+1% +$34.6K 0.64% 40
2020
Q2 		$2.93M Sell
29,826
-99
-0.3% -$8.72K 0.97% 24
2020
Q1 		$2.51M Sell
29,925
-1,025
-3% -$87.3K 0.89% 28
2019
Q4 		$2.58M Sell
30,950
-97
-0.3% -$8.05K 0.76% 29
2019
Q3 		$2.35M Buy
31,047
+961
+3% +$65.9K 0.83% 25
2019
Q2 		$2.02M Buy
30,086
+5,635
+23% +$443K 0.78% 26
2019
Q1 		$1.97M Buy
24,451
+11,387
+87% +$932K 0.8% 29
2018
Q4 		$1.2M Sell
13,064
-16,593
-56% -$1.46M 0.59% 39
2018
Q3 		$2.81M Buy
29,657
+387
+1% +$36.7K 0.79% 21
2018
Q2 		$2.71M Buy
29,270
+3,610
+14% +$353K 0.84% 15
2018
Q1 		$2.43M Sell
25,660
-5,211
-17% -$572K 0.84% 15
2017
Q4 		$2.99M Buy
30,871
+125
+0.4% +$11.8K 1.07% 8
2017
Q3 		$2.73M Sell
30,746
-988
-3% -$75.2K 1.08% 14
2017
Q2 		$2.3M Buy
31,734
+2,842
+10% +$191K 0.98% 16
2017
Q1 		$1.88M Buy
28,892
+1,490
+5% +$93.7K 0.85% 20
2016
Q4 		$1.72M Sell
27,402
-430
-2% -$26.2K 0.8% 25
2016
Q3 		$1.75M Buy
27,832
+1,264
+5% +$81.8K 0.88% 23
2016
Q2 		$1.65M Buy
26,568
+874
+3% +$53.3K 0.84% 26
2016
Q1 		$1.47M Buy
25,694
+1,046
+4% +$58.3K 0.83% 25
2015
Q4 		$1.46M Buy
+24,648
New +$1.42M 0.74% 17

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ausdal Financial Partners's ABBV Position: Q1 2026 in Review

Ausdal Financial Partners increased its AbbVie (ABBV) stake by 2% in Q1 2026, buying an estimated $172K and bringing the position to 38,690 shares worth $8.41M. The position accounts for 0.37% of the portfolio, ranked #58.

Ausdal Financial Partners first reported a position in ABBV in Q4 2015 and has held it in 42 quarters since. The position peaked at $8.82M in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Ausdal Financial Partners held 38,690 shares of AbbVie worth $8.41M as of Q1 2026.
  • Ausdal Financial Partners bought 777 AbbVie shares in Q1 2026, an estimated $172K.
  • AbbVie made up 0.37% of Ausdal Financial Partners's portfolio in Q1 2026, its #58 holding.
  • Ausdal Financial Partners first reported a position in AbbVie in Q4 2015 and has held it in 42 quarters since.
  • Ausdal Financial Partners's AbbVie position peaked at $8.82M in Q3 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Ausdal Financial Partners's 13F filing for Q1 2026, filed 12 May 2026.